KR101874250B1 - Composition for relieving and improving acute facial pain including baobab tree extract - Google Patents
Composition for relieving and improving acute facial pain including baobab tree extract Download PDFInfo
- Publication number
- KR101874250B1 KR101874250B1 KR1020170080880A KR20170080880A KR101874250B1 KR 101874250 B1 KR101874250 B1 KR 101874250B1 KR 1020170080880 A KR1020170080880 A KR 1020170080880A KR 20170080880 A KR20170080880 A KR 20170080880A KR 101874250 B1 KR101874250 B1 KR 101874250B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- pain
- composition
- facial pain
- acute
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 136
- 230000001154 acute effect Effects 0.000 title claims abstract description 92
- 206010016059 Facial pain Diseases 0.000 title claims abstract description 91
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 235000003320 Adansonia digitata Nutrition 0.000 title claims abstract description 40
- 235000003319 Adansonia gregorii Nutrition 0.000 title claims description 36
- 244000056971 Adansonia gregorii Species 0.000 title 1
- 244000056974 Adansonia digitata Species 0.000 claims abstract description 39
- 208000002193 Pain Diseases 0.000 claims description 94
- 230000036407 pain Effects 0.000 claims description 81
- 239000003814 drug Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000000419 plant extract Substances 0.000 claims description 5
- 241000234280 Liliaceae Species 0.000 claims description 4
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims 1
- 235000006008 Brassica napus var napus Nutrition 0.000 claims 1
- 240000000385 Brassica napus var. napus Species 0.000 claims 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 34
- 230000004044 response Effects 0.000 description 23
- 210000001738 temporomandibular joint Anatomy 0.000 description 22
- 239000000796 flavoring agent Substances 0.000 description 16
- 235000019634 flavors Nutrition 0.000 description 16
- 230000001815 facial effect Effects 0.000 description 14
- 238000007920 subcutaneous administration Methods 0.000 description 14
- 230000006399 behavior Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 235000013399 edible fruits Nutrition 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 208000005298 acute pain Diseases 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 210000001847 jaw Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 206010043269 Tension headache Diseases 0.000 description 6
- 208000008548 Tension-Type Headache Diseases 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010068065 Burning mouth syndrome Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 235000019629 palatability Nutrition 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 241001610232 Asarum maculatum Species 0.000 description 3
- 241000721153 Chloranthus japonicus Species 0.000 description 3
- 244000307545 Elaeagnus angustifolia Species 0.000 description 3
- 235000017643 Elaeagnus angustifolia Nutrition 0.000 description 3
- 241000471264 Elaeagnus glabra Species 0.000 description 3
- 240000000950 Hippophae rhamnoides Species 0.000 description 3
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 3
- 241000245136 Scilla scilloides Species 0.000 description 3
- 240000003451 Shepherdia argentea Species 0.000 description 3
- 235000006449 Shepherdia argentea Nutrition 0.000 description 3
- 241000681526 Spiraea prunifolia Species 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010006784 Burning sensation Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 240000000731 Fagus sylvatica Species 0.000 description 2
- 235000010099 Fagus sylvatica Nutrition 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 2
- 244000043158 Lens esculenta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004373 mandible Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003040 nociceptive effect Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019614 sour taste Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 240000000724 Berberis vulgaris Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000001375 Facial Neuralgia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000949456 Zanthoxylum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000004359 mandibular condyle Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 235000019669 taste disorders Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The present invention relates to a composition for prevention and improvement of acute facial pain including baobab tree extract. More particularly, the present invention relates to a composition for preventing and / or improving acute facial pain comprising Baobab tree extract, which prevents and improves acute facial pain using natural extracts, and which does not cause side effects even when its dose and dosage period are increased will be.
Acute facial pain is also referred to as acute oral facial pain or acute facial pain and is commonly referred to as temporal or temporal pain in temporomandibular joints such as the temporomandibular joint (jaw joint), jaw (jaw), face (face), mouth (tongue or cheek) It refers to periodic acute pain, which can be distinguished from chronic pain due to periodontal disease and the like.
Such acute facial pain may occur during dental treatment, scaling, and other dental hygiene procedures, sometimes accompanied by sudden pain, regularly or irregularly, without a certain cause.
Specifically, the acute facial pain can be classified into a centric blockage pain syndrome, a trigeminal neuralgia, a burning mouth syndrome, and a tension headache.
The cutaneous pain syndrome of the centric curvature refers to a state in which pain is sustained even when there is no external cause of pain due to sensitization in the case of damage or inflammation of the sensory nerve. In such cases, dental treatment, scaring, and other mild stimuli can cause sudden pain, small pain, and sometimes feel strange sensations other than pain. It is often associated with intermittent pain syndrome in most cases when the dentist removes it, or after receiving neuropathy or gum treatment, feels inflamed, numb, tingling or dull in the adjoining area. In addition, acute facial pain accompanied by the centripetal block syndrome is not well treated with general analgesic drugs, and antidepressants and anticonvulsants are frequently used. Recently, capsaicin cream or gabapentin is also used.
In addition, the trigeminal neuralgia can not move due to sudden electrical shocks such as sudden electricity from the face or mouth during daily life. When the moment passes, the pain disappears soon. However, when touching the face or the mouth of the mouth, It is characterized by repeated pain. Most of the patients appear in middle age or older, and pain appears on either side of the face or jaw. It does not appear on both sides. These trigeminal neuralgans have almost no therapeutic effect in general analgesics, and drugs such as carbamazepine, baclofen, and amitriptyline should be used alone or in combination. Since drugs should be used for a long time, attention should be paid to side effects and regular blood tests should be performed. If medication is not effective, surgery may be considered.
In addition, the above-mentioned oral burning sensation syndrome refers to the feeling of pain in the mucous membrane area of the tongue or mouth without any particular cause, which is mainly seen in postmenopausal women. Patients with burning mouth syndrome often present with burning sensation or painful or tingling pain in the anterior 2/3 of the tongue, in front of the palate, and in the lips. Sometimes, however, symptoms such as oral dryness and taste disorders are mixed. The exact cause of burning mouth syndrome has not yet been established, and it is presumed that changes in hormones, psychological factors, and degenerative changes in the taste buds are related. In general, amitriptyline and clonazepam may be administered or capsaicin cream may be applied to alleviate symptoms, but it is not easy to cure. For oral candidiasis, antifungal agents such as nystatin or ketoconazole should be used, and if there is a feeling of dry mouth, prescribe pilocarpine or artificial saliva.
Furthermore, the tension headache is the most frequently occurring headache, resulting in a tightening of the head or a feeling of tingling or throbbing. It usually feels pain on both sides of the head and is worse in the afternoon than in the morning. The intensity of the pain is not constant but does not appear to be severe. Stress and muscle tension are known to be the main causes of tension headaches, but other causes are also relevant. For the treatment of these tension headaches, medication therapy is mainly used, but it is possible to obtain a better therapeutic effect when the behavior therapy and physical therapy are performed together. Recently, Botox injections have been recommended as a treatment for tension headaches.
Therefore, acute facial pain according to the present invention is defined as including acute facial pain including acute facial pain syndrome, trigeminal neuralgia, burning mouth syndrome, and acute facial pain due to tension headache, including sudden and transient accompanied oral facial pain .
The acute facial pain is generally a case where acute pain does not settle even when a common analgesic is used. Even if it is effective, the acute facial pain is insignificant compared with other pain, so that there is a problem that the dosage of the analgesic is inevitably increased. Particularly, the acute facial pain is periodically generated in an irregular or irregular pattern rather than a case where it is terminated in a transient symptom, and many patients complain about pain. However, there is a problem that a specialized analgesic agent is very limited.
Therefore, it is necessary to use the natural composition so as to alleviate the acute facial pain described above, and to avoid the problem of the side effects due to the dose and the period of use by using the natural composition.
Preferably, acute facial pain in the present invention may be acute temporomandibular facial pain.
In this regard, the prior art is merely intended to provide general analgesic effects and is not directed to acute facial pain (acute oral facial pain) of the present invention. Therefore, there is no analgesic effect on acute facial pain, There is a problem that it should be considerably large.
There are many prior art techniques for facial pain as well as devices for chronic pain. Such a device has a problem in that it is difficult to use for acute facial pain as described in the present invention. Furthermore, the development of natural products related to acute facial pain is so limited that it is difficult to find.
It is an object of the present invention to provide a composition for prevention and improvement of acute facial pain originating from natural products which can alleviate acute facial pain.
The present invention also provides a composition for preventing or ameliorating acute facial pain, which can be used for irregular acute facial pain irregularly or for a long period of time because there is no problem of side effects while providing an effective relieving effect on acute facial pain by using an extract derived from natural materials.
In order to accomplish the above object, the composition for preventing and improving acute facial pain according to an embodiment of the present invention may include an extract of Adansonia digitata L. as an active ingredient.
In addition, the composition for preventing and improving acute facial pain may be selected from the group consisting of Elaeagnus glabra extract, Shepherdia argentea extract, Elaeagnus angustifolia extract, Hippophae rhamnoides extract, Or a mixture thereof.
The composition for preventing and improving acute facial pain may further comprise Scilla scilloides extract.
The composition for prevention and improvement of acute facial pain comprises at least one selected from the group consisting of barley beech extract, bacterium argententa extract, desert borealis extract, To 500 parts by weight of the extract and 20 to 500 parts by weight of the extract.
The composition for preventing and ameliorating acute facial pain is selected from the group consisting of Chloranthus japonicus Siebold extract, Asarum maculatum Nakai extract, Spiraea prunifolia for simpliciflora Nakai extract, And may include one more.
The functional food according to another embodiment of the present invention may include the composition for preventing and improving acute facial pain.
The external preparation for skin according to another embodiment of the present invention may include a composition for preventing and improving acute facial pain.
The medicament according to another embodiment of the present invention may include the composition for preventing and improving acute facial pain.
Hereinafter, the present invention will be described in more detail.
The composition for preventing and ameliorating acute facial pain according to an embodiment of the present invention may include an extract of Adansonia digitata L. as an active ingredient.
The baobab tree is native to tropical Africa, around the Mozambique Gorge, the Comoros Islands, and is a large, large, 20-meter-high tree with a diameter of 10 meters and a prominent feature. Leaflets are 5 to 7 leaflets and have a length of 25 to 30 cm with a long elliptical shape, a lanceolate shape, and an acute tip of an acupuncture point. Usually hangs down with long peduncles, and often blooms before the leaves come out. Flower color is white, petal is obovate, 10㎝ in length, and turns like an upside down. Fruits are cylindrical with a length of 10 to 40 cm and covered with hair like hair. The term " baobab tree " in the present invention is defined to include its fruit, and the term " natural product other than baobab tree "
When the Baobab tree extract is used, it is effective in preventing or alleviating acute facial pain, which is specialized for acute facial pain.
As used herein, the term " extract " means that it is used in the art as a crude extract as described above, but broadly includes fractions obtained by further fractionating the extract. That is, the extract includes not only those obtained by using the above-mentioned extraction solvent but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the extract of the present invention.
The extract used in the present invention can be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying or spray drying.
As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of an extract according to the present invention. The present invention is a composition extracted from a natural plant material, and even if administered in an excessive amount, there is no adverse effect on the human body. Therefore, the quantitative upper limit in which the extract is contained in the composition of the present invention can be selected by a person skilled in the art.
Acute facial pain " is also called acute oral facial pain or acute facial pain and is generally referred to as the temporomandibular joint (jaw joint), jaw (jaw), face (face), mouth (tongue or cheek), head, neck and shoulder Of acute pain on the part of the maxillofacial region of the mandible, which can be distinguished from chronic pain due to periodontal disease, etc. It can occur during dental treatment, scaling, and other dental hygiene procedures, and occasionally, irregularly It is accompanied by pain.
The acute facial pain is distinguished from chronic pain, and general analgesic or anti-inflammatory analgesic has a special point in that it has no effect on the acute facial pain or has an overdose.
In addition, the composition for preventing and improving acute facial pain may be selected from the group consisting of Elaeagnus glabra extract, Shepherdia argentea extract, Elaeagnus angustifolia extract, Hippophae rhamnoides extract, Or a mixture thereof.
The Elaeagnus glabra extract is an evergreen vine-grown tall tree that grows at the base of a beach. It is dense with brown hairs on the branches and has a long oval or oval lanceolate shape with a length of 4 to 8 cm and a width of 2.5 to 3.5 cm. Leaf edges are flat or dull wavy and curved. The petiole has reddish scaly hairs. Flowers bloom from October to December, several hairs are gathered from the axillae of the leaves, and fall down. The pedicel has brown scaly hairs. The fruit ripens in the fourth or the following year. It is native to Jeollanamdo and Jeju Island in Korea. It is distributed in Taiwan (Taiwan), Japan and China. The fruit is edible.
Shepherdia argentea is a plant belonging to the family Borneo and belongs to the family Borneo. It grows in the Great Plains of North America and has a strong cold character. It is bloomed from April to June and fruit is opened in August or September. The fruit is used for food.
Desert (Elaeagnus angustifolia) is a plant belonging to the family Borneo, which usually grows at a height of 5 to 7 meters. If the stems, buds, and leaves have rusty scales with silvery high density covering, the leaves are soft margins, alternate terminal tips, 4 to 9 cm. It is also distributed mainly in southern Russia and Kazakhstan, western and central Asia in Turkey, and fruit is used for food.
Hippophae rhamnoides is a bright orange fruit that is native to northern Asia and Europe and is one of the first plants to settle in the Scandinavian peninsula after the end of the ice age. It is a pioneering species with good cold tolerance and durability. It grows well in extreme climates in addition to sandy mountains and coastal areas. The Sanjay is enduring to cold, covered with long spines, and Scandinavia uses this sweet and sour fruit as a special delicacy.
The composition for preventing or ameliorating acute facial pain may be selected from the group consisting of Baobab tree extract, Barberry bean extract, Suheptodia argententa extract, Desert Borealis extract, Sanjay wood extract and mixtures thereof. The acute facial pain can be relieved or relieved, in particular acute facial pain.
On the other hand, when used alone, the extract of Sanjay has excellent effect of effectively inhibiting acute facial pain, and when used in combination with the Baobab tree extract, it has a synergistic effect of inhibiting acute facial pain . Therefore, even with a lower content, a high inhibitory effect on acute facial pain can be obtained.
Preferably, the composition for preventing and ameliorating acute facial pain may comprise an extract of Liliaceae as an active ingredient. The extract of Sanjogami extract alone can effectively reduce acute facial pain.
More preferably, the composition for preventing and ameliorating acute facial pain may include Baobab extract and Acanthopanax extract as an active ingredient. This is because the synergistic action can produce a high inhibitory effect on acute facial pain.
The composition for preventing and improving acute facial pain may further comprise Scilla scilloides extract.
Scilla scilloides is a perennial herb that grows in the mountains and mountains of Korea, and the growth environment grows anywhere in sunny places. Its height is 20 to 50cm, and the leaves are thin and long like a line, and several leaves come out from the base. The tip of the leaf is sharp, 15 to 30 cm long and 0.4 to 0.6 cm wide. The flower is dark pink, and several clusters are gathered from the upper part of the stem. The roots are 2 to 3 cm long and round in shape, and the skin is dark brown. The fruit grows in September or October, and the seed is broad and pointed.
When the above-mentioned extracts are included, acute facial pain can be more effectively reduced, so that a pain relief effect with a small amount can be obtained.
The composition for prevention and improvement of acute facial pain comprises at least one selected from the group consisting of barley beech extract, bacterium argententa extract, desert borealis extract, To 500 parts by weight of the extract and 20 to 500 parts by weight of the extract. By this range, the interaction of each extract can significantly increase to alleviate acute facial pain.
Preferably, the composition for preventing and ameliorating acute facial pain comprises 100 to 300 parts by weight of the extract of Liliaceae, and 50 to 150 parts by weight of the extract, based on 100 parts by weight of the Baobab tree extract.
According to the above range, the synergistic effect can more effectively alleviate the acute facial pain, so that the calming effect of the pain can be increased with a smaller dose.
The composition for preventing and ameliorating acute facial pain is selected from the group consisting of Chloranthus japonicus Siebold extract, Asarum maculatum Nakai extract, Spiraea prunifolia for simpliciflora Nakai extract, And may include one more.
When the extract contains Chloranthus japonicus Siebold extract, Asarum maculatum Nakai extract and Spiraea prunifolia for simpliciflora Nakai extract, the composition is excellent in flavor and can be provided as a palatable food composition .
Preferably, the composition for preventing and ameliorating acute facial pain comprises 5 to 10 parts by weight of a perennial herb extract, 5 to 10 parts by weight of a perennial herb extract, and 1 to 5 parts by weight of a perennial extract, relative to 100 parts by weight of the extract Lt; / RTI >
By the above-mentioned range, the unique sour flavor of the baobab tree can be removed, and the unique sour flavor of the baobab tree can be smoothed, thereby enhancing the flavor as a whole, and thus the flavor and palatability can be improved. Therefore, the composition within the above range can be widely used as a food composition having high palatability.
The functional food according to another embodiment of the present invention may include the composition for preventing and improving acute facial pain.
The external preparation for skin according to another embodiment of the present invention may include a composition for preventing and improving acute facial pain.
The external preparation for skin refers to a composition for external use which is used for preventing or improving acute facial pain by medicines or non-medicines.
The medicament according to another embodiment of the present invention may include the composition for preventing and improving acute facial pain.
The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract is preferably administered at a dose of 0.01 mg / kg to 10 g / kg per day, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Therefore, the dose is not intended to limit the scope of the present invention in any aspect.
&Quot; Health functional food "as defined herein means food prepared and processed using raw materials or ingredients having functionality useful to the human body in accordance with Law No. 6727 on Health Functional Foods." Functional " Structure and function of the nutrient to control or physiological effects, such as to obtain a beneficial effect for health is intended to eat.
When the extract according to the present invention is used as a food additive, the extract may be directly added or used together with other food or food ingredients, and may be suitably used according to a conventional method. Examples of the food to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.
According to the composition for preventing and improving acute facial pain resulting from the present invention, acute facial pain can be alleviated.
When the composition for preventing and improving acute facial pain is used, extracts derived from natural materials can be used for irregular acute facial pain irregularly or for a long period of time because there is no problem of side effects while effective for relieving acute facial pain.
FIG. 1 is a diagram showing a test result of a temporomandibular pain model of a composition according to an embodiment of the present invention.
Figure 2 is a test result of a temporomandibular pain model of a composition according to an embodiment of the invention.
Figure 3 relates to a facial subcutaneous pain model test result of a composition according to an embodiment of the invention.
Figure 4 relates to a facial subcutaneous pain model test result of a composition according to an embodiment of the invention.
Figure 5 relates to a test result of a temporomandibular pain model of a composition according to an embodiment of the invention.
Figure 6 is a test result of a temporomandibular pain model of a composition according to an embodiment of the invention.
Figure 7 relates to a facial subcutaneous pain model test result of a composition according to an embodiment of the invention.
Figure 8 relates to the results of a facial subcutaneous pain model test of a composition according to an embodiment of the invention.
Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[ Manufacturing example : Preparation of extract]
One. Baobab Manufacture of tree extracts
Baobab tree was extracted with hot water at 100 캜 for 4 hours using 20 times volume ratio of water. The extract was filtered with filter paper and dried under reduced pressure to prepare Baobab tree extract (B).
2. Sanjay Preparation of extract
The extracted extract was filtered with filter paper, dried under reduced pressure and dried to give a wild plant extract (V1).
3. Preparation of anti-pain extracts
The extract (V2) was prepared in the same manner as in the above extracts of the wild plants.
4. Preparation of flavor improving extract
To increase the flavor and palatability while reducing the pain, the extract of Xanthomonas rhizome (X1), the extract of Xanthi gum (X2) and the extract of Xanthoxylum japonica (X3) were prepared in the same manner as the method of producing the extract of Sanjogami.
5. Preparation of complex extract
The extracts were mixed at the mixing ratios shown in [Table 1] below to prepare complex extracts M1 to M15.
(Unit: parts by weight)
[ Experimental Example One: Sanjay For extracts Formazin Pain model test]
One. TMJ ( temporomandibular joint) model Temporomandibular joint Pain model)
TMJ (Temporomandibular joint model), Won KA, Kang YM, Lee MK, Park MK, Ju JS, Bae YC, et al.Participation of microglial p38 MAPK in formalin-induced temporomandibular joint nociception in rats J Orofac Pain 2012; 26 (2): 132-141.), And the results are shown in FIGS. 1 and 2 below.
To illustrate the specific experimental method, the experimental animals were adapted for at least 10 minutes in a laboratory plastic vat before evaluation of the pain response. After ether anesthesia, 30 μl of 5% formalin was injected into the joints, and the restoration of consciousness was observed within a few seconds after the injection of formalin. The cannula for formalin injection was connected with a 30 gauge needle at one end of the polyethylene tube and an insulin syringe (0.25 × 8 mm) at the other end. The position of the joints was estimated by palpation of the posterior lower border of the uanchral arch and the mandibular condyle, and the area where the injection needle penetrated the capsule and the mandible contacted the affected area was recognized in the joints. Through preliminary experiments, the position of the temporomandibular joint was confirmed by injecting the same amount of 1w% evans blue dye into a separate animal. After the injection of formalin, rubbing or scratching the TMJ site and the facial area was considered as a pain index. The reaction was recorded for 9 consecutive times for 5 minutes at intervals of 45 minutes, followed by a primary pain response (0-10 minutes, And pain response (11 to 45 minutes, second phase).
Referring to FIGS. 1 and 2, in the experiment using animal rat, it is possible to confirm a change in the pain behavioral response to the formalin-induced acute pain model administered to the whiskers according to the administration of the extract of Vinegar (V1). There was no significant difference between formalin infusion group, control group (vehicle + formalin infusion group) and drug infusion group at the time of administration of the extract of Vigorous plant extract (V1) In the injection group (V1 150mg / kg, 300mg / kg), pain response was significantly decreased (* p <0.05). When V1 150mg / kg was administered, the pain response was most effectively reduced at 30 minutes after the injection of the drug. In the V1 300mg / kg group, the second pain response And 15 to 40 minutes, respectively. These results suggest that the saphenous tree is effective in controlling facial acute pain.
2. SC (subcutaneous) model (facial subcutaneous pain model)
SC (subcutaneous) model (facial subcutaneous pain model, Won KA, Park SH, Kim BK, Baek KS, Yoon DH, Ahn DK. Intracisternal Administration of Voltage Dependent Calcium Channel Blockers Attenuates Orofacial Inflammatory Nociceptive Behavior in Rats. Int J Oral Biol 2011 ; Effects of intracisternal injection of interleukin-6 on nociceptive jaw opening reflex and oropharyngeal formalin test in freely moving rats (2): 43-50.; Choi HS, Ju JS, Lee HJ, Kim BC, Park JS, Brain Res Bull 2003; 59 (5): 365-370.), And the results are shown in FIGS. 3 and 4 below.
To illustrate the specific experimental method, the experimental animals were adapted for at least 10 minutes in a laboratory plastic vat before evaluation of the pain response. Injection of 5% formalin (50 μl) into the right shoulder of the experimental animals was performed using an insulin syringe (0.25 m (31 G) m × mm) and rubbing or scraping of the face was regarded as a pain index. A total of 45 minutes of cumulative behavioral response was observed from immediately after the injection to the 5th minute. The response was evaluated by dividing into the first pain response (0-10 minutes, first phase) and the second pain response (11-45 minutes, second phase) Respectively.
Referring to FIGS. 3 and 4 below, the changes in the pain behavior response to the administration of the extract of Vinegar (V1) in the formalin-induced acute facial pain model administered to the jaw joint in an experiment using an animal (Rat) have. There was no significant difference between formalin infusion group, control group (vehicle + formalin infusion group) and drug infusion group in the first pain action reaction during the administration of the extract of Vigorous Lentil (V1) (P <0.05), the pain response behaviors were significantly reduced in the drug-injected group (150 mg / kg, 300 mg / kg). When V1 was administered at 150 mg / kg, the pain response was most effectively decreased at 25 minutes after the administration of V1, and at 30 minutes after
[ Experimental Example 2: Baobab For extracts Formazin Pain model test]
One. TMJ ( temporomandibular joint) model Temporomandibular joint Pain model)
In the same manner as above, the effect of the baobab tree extract (B) on the acute facial pain relief effect through the temporomandibular joint pain model was examined. The results are shown in FIGS. 5 and 6.
Referring to FIGS. 5 and 6 below, the effect of administration of the baobab tree extract on the concentration can be confirmed. The baobab extract also showed a marked decrease in the secondary pain response in the drug - infused group compared to the control (vehicle + formalin - infused group). When the pain relieving effect of the baobab tree extract was examined over time, the pain behavior reaction was most effectively decreased at the time of 30 minutes of drug administration at 150 mg / kg of Bao, and 25 to 30 minutes at the 300 mg / kg of baobab tree extract At the time point, pain response was reduced. These results suggest that baobab can effectively control TMJ pain behavior.
2. SC (subcutaneous) model (facial subcutaneous pain model)
In the same manner as described above, the effect of the baobab tree extract (B) on the acute facial pain relief effect through the facial subcutaneous pain model was investigated. The results are shown in FIGS. 7 and 8.
Referring to FIGS. 7 and 8, a change in the pain behavior response to the administration of baobab in the formalin-induced acute pain model injected into the facial area of an experimental animal can be confirmed. There was no statistically significant difference in the primary pain behavioral response between the baalex extract and the formalin infusion group, the control group (vehicle + formalin infusion group) and the drug infusion group. However,
[ Experimental Example 2: for mixed extracts Formazin Pain model test]
One. TMJ ( temporomandibular joint) model Temporomandibular joint Pain model)
In order to confirm the synergistic effect of the combined extracts M1 to M11 on the acute facial pain relief, experiments were conducted on the basis of 300 mg / kg in the same manner as the Baobab tree extract (B) using the TMJ model. The results are shown in Table 2 below in comparison with the baobab extract (B). In the following Table 2, each index was expressed as 1 to 20 as an exponent by comparing the pain behavioral responses at 25 minutes for each compound extract with 25
(25 min)
(Unit: index)
Referring to the above Table 2, it can be seen that when the compound extract is used, the pain activity is reduced and the compound extract is more effective for pain relief. In particular, when M2 to M4 are used, the effect of alleviating the acute pain induced in the temporomandibular joint is high, so that it is possible to obtain a high analgesic effect with a smaller content. Also, referring to M8 to M10, it can be seen that when the extracts are used in a certain range, there is an additional synergistic effect due to the interaction.
2. SC (subcutaneous) model (facial subcutaneous pain model)
The effects of mixed extracts M1 to M11 on the acute facial pain were examined using the facial subcutaneous pain model. The experiment was conducted on the basis of 300 mg / kg in the same manner as the Baobab tree extract (B). The results are shown in Table 3 below in comparison with the baobab extract (B). In the following Table 3, each index was expressed as 1 to 20 as an exponent of the pain behavioral responses at 25 minutes for each compound extract, with 25
(25 min)
(Unit: index)
Referring to Table 3, it can be seen that the combined extracts M2 to M4 reduce the pain activity and that the combined extract is more effective for relieving pain, and the additional synergistic effect is exhibited by M8 to M10 .
[ Experimental Example 3: palatability test]
One. Sensuality Evaluation experiment
B, M4 and M12 to M15 of the combined extracts were diluted to prepare tea beverages. The tea drink was tasted by a tasting person of 10 people, and the taste and flavor were represented by an index of 1 to 10. The average value (0.5 rounded) was shown in Table 4 below. The higher the number, the higher the preference.
(Unit: index)
Referring to Table 4, in the case of B, in addition to the sour flavor of the baobab tree, the flavor was sour and sour, accompanied by a sour taste and sour flavor, and when M4 was mixed, the sour flavor became stronger and the sour flavor became lower . On the other hand, according to the combined extracts M13 to M14, it was found that the sweet taste and sour taste, which are unique to Sanjayu, are neutralized and the flavor of the spices is enhanced.
Therefore, it is possible to provide a functional food which is effective for alleviating acute facial pain with flavor and taste which is higher in preference than the case of using the combined extracts M13 to M14.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments, Of the right.
Claims (8)
The acute facial pain is acute temporomandibular pain,
The composition comprises an extract of Baobab (Adansonia digitata L.), an extract of Liliaceae, and an extract of the present invention as active ingredients,
With respect to 100 parts by weight of the Baobab tree extract,
100 parts by weight to 300 parts by weight of the extract of Liliaceae and 50 to 150 parts by weight of the extract,
In order to improve the preference of the composition, the composition further comprises a perennial flower extract, a canola grass extract and a corn tree extract,
5 to 10 parts by weight of a perennial plant extract, 5 to 10 parts by weight of a plant extract, and 1 to 5 parts by weight of a plant extract are added to 100 parts by weight of the above-
A composition for preventing and improving acute facial pain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170080880A KR101874250B1 (en) | 2017-06-27 | 2017-06-27 | Composition for relieving and improving acute facial pain including baobab tree extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170080880A KR101874250B1 (en) | 2017-06-27 | 2017-06-27 | Composition for relieving and improving acute facial pain including baobab tree extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101874250B1 true KR101874250B1 (en) | 2018-07-05 |
Family
ID=62920110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170080880A KR101874250B1 (en) | 2017-06-27 | 2017-06-27 | Composition for relieving and improving acute facial pain including baobab tree extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101874250B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200077093A (en) * | 2018-12-20 | 2020-06-30 | 동의대학교 산학협력단 | Composition for relieving and improving acute facial pain containing boswellia extract and seabuckthorn extract |
-
2017
- 2017-06-27 KR KR1020170080880A patent/KR101874250B1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| 김윤경 외 3명, ‘포르말린으로 유발된 안면부 통증조절에서 사물탕의 역할’, Journal of the Korea Academia-Industrial cooperation Society 제15권제9호, 5594-5601쪽, 2014년. |
| 무릇 효능과 부작용, 주의사항 (네이버 블로그, https://blog.naver.com/dongmu61/30175380353) (2013.09.05.) |
| 바오밥나무 전설::거꾸로 박힌 나무 (네이버 블로그, https://blog.naver.com/bsvjgugp2/220353332124) (발행일 2015.05.08.) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200077093A (en) * | 2018-12-20 | 2020-06-30 | 동의대학교 산학협력단 | Composition for relieving and improving acute facial pain containing boswellia extract and seabuckthorn extract |
| KR102156627B1 (en) * | 2018-12-20 | 2020-09-16 | 동의대학교 산학협력단 | Composition for relieving and improving acute facial pain containing boswellia extract and seabuckthorn extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013051727A1 (en) | Agent for improving quality of sleep | |
| KR101874250B1 (en) | Composition for relieving and improving acute facial pain including baobab tree extract | |
| KR101948047B1 (en) | Composition for relieving and improving acute facial pain containing boswellia extract | |
| CN109645549A (en) | A kind of cigarette of smoking cessation | |
| CN102919499A (en) | Sugar-free health care chewing gum | |
| CN103330175B (en) | Seasoning made of natural plant compositions and preparation method thereof | |
| JPH0832631B2 (en) | Food and drink for mental stability | |
| KR101911838B1 (en) | Composition for relieving and improving acute facial pain | |
| KR102141623B1 (en) | Composition for prevention or treatment of dental disease comprising an extract of cinnamon | |
| KR101944113B1 (en) | Composition for relieving and improving acute facial pain | |
| KR102318032B1 (en) | Composition for prevention and alleviation of inflammation and neuropathic pain | |
| KR102156627B1 (en) | Composition for relieving and improving acute facial pain containing boswellia extract and seabuckthorn extract | |
| KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
| KR102163889B1 (en) | Composition for preventing and treating of neuropathic pain containing nypa fruticans wurmb extract | |
| KR102156438B1 (en) | Composition for relieving and improving acute facial pain | |
| KR20110019977A (en) | Composition for protection and treatment of stress and panic disorder | |
| CN106974285B (en) | Traditional Chinese medicine composition and application thereof | |
| KR102433007B1 (en) | Composition for preventing and treating of neuropathic pain containing saussurea neoserrata extract | |
| KR20140115228A (en) | Composition for prevention or treatment of hair loss comprising oriental herbal extracts | |
| KR102319382B1 (en) | For antioxidant, antidepressant and antistress compositions comprising boswellia | |
| KR20190016754A (en) | A pharmaceutical composition comprising tetragonia tetragonoides extract for preventing or treating depression | |
| CN107233490A (en) | A kind of maca composition of supplementing qi and nourishing yin beautifying face and moistering lotion | |
| KR20230045187A (en) | Composition for preventing or improving sarcopenia comprising herbal extract and brewer's yeast powder as active ingredients | |
| KR20090013956A (en) | Composition for improving erectile dysfunction and erection maintenance comprising the extract of crude drug complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |